Hosted on MSN1mon
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective peroxisome proliferator-activated receptor alpha (PPAR-α) antagonist ...
Psychology Today2y
Oppositional Defiance (ODD) Therapists in New Jersey
The treatment of Oppositional defiant disorder (ODD) will involve multiple approaches designed to help both the youngster and their parents, sometimes including medication. A therapist will help a ...
Psychology Today1y
Oppositional Defiance (ODD) Therapists in Massachusetts
The treatment of Oppositional defiant disorder (ODD) will involve multiple approaches designed to help both the youngster and their parents, sometimes including medication. A therapist will help a ...
Targeted Oncology8d
FDA Grants 225Ac-SSO110 Orphan Drug Status in SCLC
Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...
News Medical on MSN5d
Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...
PharmiWeb3d
Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...